Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet, vol.387, pp.1405-1419, 2016. ,
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial, Lancet Oncol, vol.14, pp.1104-1115, 2013. ,
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial, Lancet Oncol, vol.18, issue.17, pp.30446-30447, 2017. ,
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, openlabel, randomised, non-comparative, phase 2 trial, Lancet Oncol, vol.20, pp.239-53, 2019. ,
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity, Sci Transl Med, vol.6, pp.261-151, 2014. ,
Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human, Clin Cancer Res, vol.24, pp.766-76, 2018. ,
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies, Cancer Immunol Res, vol.2, pp.112-132, 2014. ,
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell immunotherapy for mesothelioma (DENIM) trial, Transl Lung Cancer Res, vol.8, pp.280-285, 2019. ,
Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma, Am J Respir Crit Care Med, vol.193, pp.1023-1054, 2016. ,
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma, Am J Respir Crit Care Med, vol.181, pp.1383-90, 2010. ,
Identification of ALK rearrangements in malignant peritoneal mesothelioma, JAMA Oncol, vol.4, pp.235-243, 2018. ,
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X, Mod Pathol, vol.30, pp.246-54, 2017. ,
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma, Genome Med, 2019. ,
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, vol.48, pp.407-423, 2016. ,
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma, Arch Pathol Lab Med, vol.136, pp.13432-13439, 2012. ,
Neoantigenic potential of complex chromosomal rearrangements in mesothelioma, J Thorac Oncol, vol.14, pp.276-87, 2019. ,
Integrative molecular characterization of malignant pleural mesothelioma, Cancer Discov, vol.8, pp.1548-65, 2018. ,
Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma, Oncogene, vol.33, pp.3748-52, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478602
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma, Cancer Lett, vol.405, pp.38-45, 2017. ,
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy, Proc Natl Acad Sci, vol.116, pp.9008-9021, 2019. ,
Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma, J Clin Oncol, vol.36, pp.2863-71, 2018. ,
A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations, J Clin Oncol, vol.36, pp.3485-94, 2018. ,
Germline BAP1 mutations predispose to malignant mesothelioma, Nat Genet, vol.43, pp.1022-1027, 2011. ,
Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome, Cancer Res, vol.69, pp.227-261, 2009. ,
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma, Cancer Res, vol.69, pp.9073-82, 2009. ,
Targeting the epigenome in malignant pleural mesothelioma, Transl Lung Cancer Res, vol.6, pp.350-65, 2017. ,
Loss of BAP1 function leads to EZH2-dependent transformation, Nat Med, vol.21, pp.1344-1353, 2015. ,
Non-coding transcript heterogeneity in mesothelioma: insights from asbestos-exposed mice, Int J Mol Sci, vol.19, p.1163, 2018. ,
MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets, J Thorac Dis, vol.7, pp.1031-1071, 2015. ,
In silico and in vitro analyses of LncRNAs as potential regulators in the transition from the epithelioid to sarcomatoid histotype of malignant pleural mesothelioma (MPM), Int J Mol Sci, vol.19, p.1297, 2018. ,
Biomolecular pathways and malignant pleural mesothelioma, Malignant Pleural Mesothelioma: Present Status and Future Directions, pp.169-92, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02479956
Novel insights into mesothelioma biology and implications for therapy, Nat Rev Cancer, vol.17, pp.475-88, 2017. ,
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the international mesothelioma interest group, Arch Pathol Lab Med, vol.137, pp.647-67, 2013. ,
Heterogeneity in Malignant Pleural Mesothelioma, Int J Mol Sci, p.19, 2018. ,
Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelialto-mesenchymal transition, Clin Cancer Res, vol.20, pp.1323-1357, 2014. ,
Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma, Clin Cancer Res, vol.23, pp.3191-202, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478604
Dissecting heterogeneity in malignant pleural mesothelioma through histomolecular gradients for clinical applications, Nat Commun, vol.10, p.1333, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02090279
Unraveling the cellular heterogeneity of malignant pleural mesothelioma through a deconvolution approach, Mol Cell Oncol, vol.6, p.1610322, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478611
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions, EBioMedicine, vol.48, pp.191-202, 2019. ,
Evaluation of clonal origin of malignant mesothelioma, J Transl Med, vol.12, p.301, 2014. ,
Wholegenome sequencing of human malignant mesothelioma tumours and cell lines, Carcinogenesis, vol.40, pp.724-758, 2019. ,
Heterogeneity in immune cell content in malignant pleural mesothelioma, Int J Mol Sci, vol.19, p.1041, 2018. ,
Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma, J Thorac Oncol, vol.14, pp.1458-71, 2019. ,
Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma, Oncoimmunology, vol.6, p.1278330, 2017. ,
Classifying the evolutionary and ecological features of neoplasms, Nat Rev Cancer, vol.17, pp.605-624, 2017. ,
Scientific advances and new frontiers in mesothelioma therapeutics, J Thorac Oncol, vol.13, pp.1269-83, 2018. ,
Gene therapy for malignant mesothelioma: current prospects and challenges, Cancer Gene Ther, vol.20, pp.150-156, 2013. ,
Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model, Int J Oncol, vol.48, pp.1399-407, 2016. ,
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma, Br J Pharmacol, vol.166, pp.532-53, 2012. ,
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin, Br J Cancer, vol.105, pp.1542-53, 2011. ,
The role of alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials ,
, Lung Cancer, pp.121-125, 2004.
SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma, Int J Cancer, vol.132, pp.459-71, 2013. ,
Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells, Curr Drug Targets, vol.15, pp.1331-1371, 2014. ,
Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma, Acta Med Okayama, vol.68, pp.23-29, 2014. ,
Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed, J Control Release, vol.220, pp.29-36, 2015. ,
Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesotheliomadagger, Eur J Cardiothorac Surg, vol.47, pp.34-41, 2015. ,
Monitoring of tumour progression using bioluminescence imaging and computed tomography scanning in a nude mouse orthotopic model of human small cell lung cancer, Lung Cancer, vol.77, pp.70-76, 2012. ,
Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1-and HER2-targeted radiolabeled antibodies, Radiology, vol.267, pp.173-82, 2013. ,
Studies of a human mesothelioma, Hum Pathol, vol.13, pp.862-868, 1982. ,
Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model, Cancer Res, vol.47, pp.3199-205, 1987. ,
Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am J Pathol, vol.178, pp.1033-1075, 2011. ,
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma, Am J Pathol, vol.178, pp.881-94, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00531343
Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma, Lung Cancer, vol.126, pp.15-24, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478609
In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines, Int J Cancer, vol.55, pp.515-535, 1993. ,
Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies, Hum Pathol, vol.25, pp.227-261, 1994. ,
Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease, Cell Death Differ, vol.23, pp.1152-64, 2016. ,
Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis, Mol Cancer, vol.17, p.148, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01904612
A conditional mouse model for malignant mesothelioma, Cancer Cell, vol.13, pp.261-71, 2008. ,
Mesotheliomas in Genetically engineered mice unravel mechanism of mesothelial carcinogenesis, Int J Mol Sci, vol.19, p.2191, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478607
Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models, Cancer Res, vol.79, pp.4113-4136, 2019. ,
Animal models of disease: preclinical animal models of cancer and their applications and utility in drug discovery, Biochem Pharmacol, vol.87, pp.150-61, 2014. ,
Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes, Cancer Res, vol.72, pp.2695-700, 2012. ,
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial, Lancet Respir Med, vol.7, issue.18, p.30420, 2019. ,
CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial, Trials, vol.19, p.233, 2018. ,
Nivo-lution in mesothelioma, Clin Cancer Res, vol.25, pp.5438-5478, 2019. ,
Acute injury and regeneration of the mesothelium in response to asbestos fibers, Am J Pathol, vol.128, pp.426-471, 1987. ,
,
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2, J Immunol, vol.171, pp.5051-63, 2003. ,
Establishment of a murine model of malignant mesothelioma, Int J Cancer, vol.52, pp.881-887, 1992. ,
Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats, Am J Pathol, vol.129, pp.448-62, 1987. ,
Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine, Oncotarget, vol.7, pp.34664-87, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01306838
Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma, Oncotarget, vol.9, pp.16311-16340, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01726393
Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model, Lung Cancer, vol.71, pp.370-371, 2011. ,
The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer, Mol Cancer Ther, vol.8, pp.2221-2252, 2009. ,
The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma, J Mol Med, vol.97, pp.231-273, 2019. ,
Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma, J Exp Clin Cancer Res, vol.38, p.349, 2019. ,
Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model, Cancer Sci, vol.107, pp.1198-205, 2016. ,
Anetumab ravtansine: a novel mesothelin-targeting antibodydrug conjugate cures tumors with heterogeneous target expression favored by bystander effect, Mol Cancer Ther, vol.13, pp.1537-1585, 2014. ,
Podoplanin: an emerging cancer biomarker and therapeutic target, Cancer Sci, vol.109, pp.1292-1301, 2018. ,
An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models, Mol Cancer Ther, vol.13, pp.2630-2670, 2014. ,
New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma, Sci Rep, vol.5, p.9928, 2015. ,
Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a biomarker of tumor response, Clin Cancer Res, vol.23, pp.1564-74, 2017. ,
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelinspecific chimeric antibody receptor, Clin Cancer Res, vol.17, pp.4719-4749, 2011. ,
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor, Cancer Res, vol.70, pp.9053-61, 2010. ,
The generation and application of patient-derived xenograft model for cancer research, Cancer Res Treat, vol.50, pp.1-10, 2018. ,
Transplantation of human malignant mesothelioma into nude mice, Cancer Res, vol.40, pp.181-186, 1980. ,
Patient-derived xenograft establishment from human malignant pleural mesothelioma, Clin Cancer Res, vol.23, pp.1060-1067, 2017. ,
Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain, Immunity, vol.2, pp.223-261, 1995. ,
Dangles-Marie V. Spherical cancer models in tumor biology, Neoplasia, vol.17, pp.1-15, 2015. ,
Changes in global gene expression associated with 3D structure of tumors: an ex vivo matrix-free mesothelioma spheroid model, PLoS ONE, vol.7, p.39556, 2012. ,
Analysis of gene expression in 3D spheroids highlights a survival role for ASS1 in mesothelioma, PLoS ONE, vol.11, 2016. ,
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids, J Biol Chem, vol.283, pp.13021-13051, 2008. ,
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of noxa expression, PLoS ONE, vol.7, p.52753, 2012. ,
Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates, Cell Death Differ, vol.16, pp.1146-55, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00388174
2-Deoxy-glucose enhances the effect of cisplatin and pemetrexed in reducing malignant pleural mesothelioma cell proliferation but not spheroid growth, Anticancer Res, vol.39, pp.3809-3823, 2019. ,
Paclitaxelloaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids, J Thorac Cardiovasc Surg, vol.149, pp.1417-1441, 2015. ,
PEGylated anionic magnetofluorescent nanoassemblies: impact of their interface structure on magnetic resonance imaging contrast and cellular uptake, ACS Appl Mater Interfaces, vol.9, pp.14242-57, 2017. ,
Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy, J Cancer, vol.2, pp.507-521, 2011. ,
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy, PLoS ONE, vol.6, 2011. ,
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance, Cell Death Dis, vol.2, 2011. ,
Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors, Cell Death Dis, vol.6, p.1757, 2015. ,
Autophagy initiation correlates with the autophagic flux in 3D models of mesothelioma and with patient outcome, Autophagy, vol.12, pp.1180-94, 2016. ,
A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance, Am J Respir Cell Mol Biol, vol.33, pp.541-549, 2005. ,
Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model, PLoS ONE, vol.12, p.182039, 2017. ,
Mimicking the tumor microenvironment to regulate macrophage phenotype and assessing chemotherapeutic efficacy in embedded cancer cell/macrophage spheroid models, Acta Biomater, vol.50, pp.271-280, 2017. ,
3D-3-culture: a tool to unveil macrophage plasticity in the tumour microenvironment, Biomaterials, vol.163, pp.185-97, 2018. ,
Translating cancer research into targeted therapeutics, Nature, vol.467, pp.543-552, 2010. ,
How can attrition rates be reduced in cancer drug discovery?, Exp Opin Drug Discov, vol.8, pp.363-371, 2013. ,
The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease, Eur J Pharmacol, vol.759, pp.19-29, 2015. ,
In silico cancer research towards 3R, BMC Cancer, vol.18, p.408, 2018. ,
Organ-on-a-chip for cancer and immune organs modeling, Adv Healthc Mater, vol.8, p.1801363, 2019. ,
Drug development: raise standards for preclinical cancer research, Nature, vol.483, pp.531-534, 2012. ,
Consider drug efficacy before first-in-human trials, Nature, vol.542, pp.25-32, 2017. ,